Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.21.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Product Information [Line Items]          
Cash FDIC insurance $ 250,000   $ 250,000    
Cash SIPC insurance 500,000   500,000    
Patent and licensing costs 137,114 $ 163,987 365,466 $ 440,899  
Unrecognized tax benefits $ 0   $ 0   $ 0
Deferred setup and organization costs, amortization period     12 months    
Cost of Sales [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]          
Product Information [Line Items]          
Concentration of risk, percentage     10.00%    
General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]          
Product Information [Line Items]          
Concentration of risk, percentage 13.60% 20.40% 9.70% 32.70%  
General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member] | Stock Options Granted to Three Corporate Officers [Member]          
Product Information [Line Items]          
Concentration of risk, percentage   49.10% 29.20%    
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]          
Product Information [Line Items]          
Concentration of risk, percentage   87.70%   75.20%  
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customers [Member]          
Product Information [Line Items]          
Concentration of risk, percentage 49.10%   33.20%    
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]          
Product Information [Line Items]          
Concentration of risk, percentage 13.50%   26.90%    
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Three Customers [Member]          
Product Information [Line Items]          
Concentration of risk, percentage 13.20%   10.50%    
Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Four Customers [Member]          
Product Information [Line Items]          
Concentration of risk, percentage 12.70%